1-2 of 2
Zong-Fang Li, MD PhD
Close
Sort by
Journal Articles

Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Bai-Yan Wang, MD PhD, Wan-Hong Zhao, MD PhD, Jie Liu, MD, Yin-Xia Chen, MD, Xing-Mei Cao, MD, Yun Yang, MD, Yi-Lin Zhang, MD, Fang-Xia Wang, MD PhD, Peng-Yu Zhang, MD PhD, Bo Lei, MD, Liu-Fang Gu, MD PhD, Jian-Li Wang, MD PhD, Jia-Jia Zhang, MD, Ru Zhang, MD, Hui Zhang, MD, Ying Shen, MD, Ju Bai, PhD, Yan Xu, MD, Xu-Geng Wang, MD PhD, Rui-Li Zhang, MD, Li-Li Wei, MD, Zong-Fang Li, MD PhD, Gai-Xia He, PhD, Yan Geng, MD PhD, Qian He, MD PhD, Qiu-Chuan Zhuang, Msc, Frank Xiao-Hu Fan, MD PhD, Wang-Gang Zhang, MD PhD, Ai-Li He, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 579.
https://doi.org/10.1182/blood-2019-124953
Published: 2019
Journal Articles

Updated Analysis of a Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients with Relapsed/Refractory Multiple Myeloma

Wan-Hong Zhao, MD PhD, Jie Liu, MD, Bai-Yan Wang, MD PhD, Yin-Xia Chen, MD, Xing-Mei Cao, MD, Yun Yang, MD, Yi-Lin Zhang, MD, Fang-Xia Wang, MD PhD, Peng-Yu Zhang, MD PhD, Bo Lei, MD, Liu-Fang Gu, MD PhD, Jian-Li Wang, MD PhD, Nan Yang, MD, Ru Zhang, MD, Hui Zhang, MD, Ying Shen, MD, Ju Bai, PhD, Yan Xu, Xu-Geng Wang, MD PhD, Rui-Li Zhang, MD, Li-Li Wei, MD, Zong-Fang Li, MD PhD, Zhen-Zhen Li, PhD, Yan Geng, MD PhD, Qian He, MD PhD, Qiu-Chuan Zhuang, Msc, Frank Xiao-Hu Fan, MD PhD, Ai-Li He, MD PhD, Wang-Gang Zhang, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 955.
https://doi.org/10.1182/blood-2018-99-110548
Published: 2018